Autologous dendritic cells pulsed with allogeneic tumour cell lysate induce tumour-reactive T-cell responses in patients with pancreatic cancer

Autor: Lau, S.P., Klaase, L., Vink, M., Dumas, J., Bezemer, K., Krimpen, A. van, Breggen, R. van der, Wismans, L.V., Doukas, M., Koning, W. de, Stubbs, A.P., Mustafa, D.A.M., Vroman, H., Stadhouders, R., Nunes, J.B., Stingl, C., Miranda, N.F.C.C. de, Luider, T.M., Burg, S.H.V., Aerts, J.G., Eijck, C.H.J. van

Publikováno v: European Journal of Cancer, 169, 20-31. ELSEVIER SCI LTD
European Journal of Cancer, 169, 20-31. Elsevier Ltd.

Background: Pancreatic ductal adenocarcinoma (PDAC) is notorious for its poor prognosis even after curative resection. Responses to immunotherapy are rare and related to inadequate T-cell priming. We previously demonstrated the potency of allogeneic

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::43c0d56802ec6d3517d28ec19151715b
https://pure.eur.nl/en/publications/a499c0b9-6800-4111-be73-4cb8b0817bd7

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

A multicenter, randomized, phase II/III study of dendritic cells loaded with allogeneic tumor cell lysate (MesoPher) in subjects with mesothelioma as maintenance therapy after chemotherapy: DENdritic cell Immunotherapy for Mesothelioma (DENIM) trial

Autor: Belderbos, Robert A., Baas, Paul, Berardi, Rossana, Cornelissen, Robin, Fennell, Dean A., van Meerbeeck, Jan, Scherpereel, Arnaud, Vroman, Heleen, Aerts, Joachim G. J., V, Bezemer, K., Rafaelian, A., Poncin, M., Goktas, I, Braakman, E., van Hove, L., Klok, J., Geel, A., de Vries, M., Janssens, Annelies, Zhang, Xiang, Raskin, Jo, Kohl, Siska, Hufkens, Annemie, Claes, Rita, Willemin, M. C., Wasielewski, E., Grammont, M., Batista, S., Pinturaud, M., Ballatore, Z., Lucarelli, A., Burattini, M., Tonnini, C., Bianchi, F., Pagliaretta, S., Hudka, M., Lord, K., Darlison, L., Varadhan, B., Hunter, A.

Publikováno v: Translational lung cancer research
Translational Lung Cancer Research, 8(3), 280-285. Society for Translational Medicine (STM)
Translational Lung Cancer Research

BACKGROUND: Malignant pleural mesothelioma (MPM) is an aggressive, treatment resistant neoplasm. The current treatment, consisting of antifolate and platinum-based chemotherapy, improves the median overall survival with only 3 months. Adjuvant bevaci

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9f521f512f42d764c2b193c5aaf43990
https://hdl.handle.net/10067/1613550151162165141

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.